Neuroscience
Focused Ultrasound and the Future of Alzheimer's Treatment
Recent trials using focused ultrasound to open the blood-brain barrier and reduce amyloid plaque have rightly captured attention. A careful read of what the technology can and cannot do.
Headlines this year have declared Alzheimer's "curable" thanks to focused ultrasound. The underlying science is genuinely exciting. The headline is not quite right. Both deserve a careful read.
Focused ultrasound is a noninvasive technique that uses precisely targeted sound waves, guided by MRI, to temporarily open the blood-brain barrier in a defined region. That brief opening allows the immune system better access to brain tissue, and, in combination with antibody therapies such as aducanumab and lecanemab, has been shown to accelerate the clearance of amyloid plaques.
What the trials actually showed
In the most cited West Virginia University and Sunnybrook studies, patients with mild Alzheimer's who received focused ultrasound in addition to anti-amyloid antibody therapy showed amyloid reduction in the targeted brain regions on PET imaging compared with untreated regions. Cognitive endpoints were promising but preliminary. These were small, early-phase studies, not the definitive trials that change practice.
“"Cureable" is the wrong word. "Newly modifiable" is the honest one.”
Why this matters even if it is not a cure
For decades, Alzheimer's research was stuck. Amyloid hypotheses produced therapies that barely moved the needle clinically. Focused ultrasound is meaningful because it changes the delivery problem. It makes therapeutic molecules more available to the diseased tissue, which is the bottleneck many drug candidates have run into.
Where it does not change the conversation
Even in the best case, focused ultrasound is a downstream intervention. It does not address the upstream drivers of neurodegeneration, the metabolic and vascular and hormonal changes that quietly damage the brain for two decades before symptoms emerge. Patients who hear "cure" sometimes interpret it as permission to defer the boring, durable work of brain longevity. That would be a mistake.
How I am advising patients
Stay informed, do not chase clinical trials prematurely, and continue investing in the modifiable risk factors with the strongest evidence: sleep, glucose control, cardiovascular fitness, muscle mass, social engagement, and hormonal health. Focused ultrasound is an important new tool. It is not a substitute for the decades of upstream work that make any downstream therapy more likely to succeed.
About the author
Dr. Marissa McCarthy
Board certified in Physical Medicine & Rehabilitation with sub-specialty certification in Brain Injury Medicine. Founder of Raeven Health, a concierge practice in Tampa, Florida.
Read full bio